NOT-OD-22-007: Flexibility Available to Lasker Clinical Research Scholars Affected by COVID-19

Flexibility Available to Lasker Clinical Research Scholars Affected by COVID-19

Notice Number:

NOT-OD-22-007

Key Dates

Release Date:

October 21, 2021

Related Announcements

PAR-20-315 - Limited Competition: Lasker Clinical Research Scholars Transition Award (R00 Clinical Trial Optional)
PAR-20-167 - Lasker Clinical Research Scholars Program (Si2/R00)
PAR-19-262 - Lasker Clinical Research Scholars Program (Si2/R00)
PAR-18-740 - Lasker Clinical Research Scholars Program (Si2/R00)
PAR-17-254 - Lasker Clinical Research Scholars Program (Si2/R00)
PAR-16-203 - Lasker Clinical Research Scholars Program (Si2/R00)
PAR-15-189 - Lasker Clinical Research Scholars Program (Si2/R00)
RFA-OD-14-004 - Lasker Clinical Research Scholars Program (Si2)
RFA-OD-13-004 - Lasker Clinical Research Scholars Program (Si2)
RFA-OD-12-001 - Lasker Clinical Research Scholars Program (Si2)

Issued by

NATIONAL INSTITUTES OF HEALTH (NIH)

Purpose

The NIH is concerned about the effects of the COVID-19 public health emergency on the biomedical enterprise. To mitigate lost productivity due to the public health emergency, Lasker Clinical Research Scholars currently in the intramural Si2 phase of their award may request a one-year extension of the Si2 phase. The Scholars, with concurrence from their Scientific Director, should submit the request to the NIH Deputy Director for Intramural Research. This extension will provide the Scholars an additional year of eligibility before they need to apply for the extramural R00 phase.

Inquiries

Please direct all inquiries to:

Charles R. Dearolf, Ph.D.
Director, Program Development and Support
Office of Intramural Research
National Institutes of Health
Building 1, Room 152
Bethesda, MD 20892
email: dearolfc@od.nih.gov